Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Celltrion to Launch 1st Stelara IV Biosimilar on August 20
Celltrion Healthcare Japan will roll out a biosimilar of Stelara IV (ustekinumab) on August 20, becoming the first company to market a follow-on version of the intravenous formulation of Janssen Pharmaceutical’s (J&J) major IBD treatment in Japan. While four companies,…
To read the full story
Related Article
BUSINESS
- Lilly Blasts Mounjaro Price Cut, Warns over Japan Investment Appeal
August 4, 2026
- Kyowa Kirin Profits Surge as R&D Costs Fall, Overseas Sales Grow
August 4, 2026
- Leqembi Leads US Anti-Amyloid Market; Eisai Sees Iqlik Reshaping AD Care
August 4, 2026
- Kyorin to Begin Co-Promoting Alesion Eyelid Cream on August 17
August 4, 2026
- Fujifilm, Taiho Forge Strategic Partnership on ADC Manufacturing
August 4, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…